Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522937 · ClinicalTrials.gov registry record · Phase 2
A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
A Phase 2 study of Liver Cancer and Hepatocellular Cancer, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
- 1
- Study location
NCT01522937 is a Phase 2 study of Liver Cancer and Hepatocellular Cancer that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 94 participants, below the 447-participant average among 78 other Liver Cancer trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01522937, a Phase 2 study of Liver Cancer and Hepatocellular Cancer, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase II trial to characterize the safety and efficacy of individualized stereotactic body radiation therapy (SRBT) for patients who have had previous liver treatment or who have primary hepatocellular carcinoma (HCC).
Conditions Studied
Interventions
- RADIATION individualized Stereotactic Body Radiation Therapy (SBRT)
Study Locations (1)
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2009-10 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01522937
The ClinicalTrials.gov registry entry for NCT01522937 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 447-participant average among 78 other Liver Cancer trials with a reported enrollment target (79% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which individualized Stereotactic Body Radiation Therapy (SBRT) is the first listed.
NCT01522937 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT01522937 about?
NCT01522937 is a clinical study titled "A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer". This is a Phase II trial to characterize the safety and efficacy of individualized stereotactic body radiation therapy (SRBT) for patients who have had previous liver treatment or who have primary hepatocellular carcinoma (HCC).
What is the current status of trial NCT01522937?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2009-10. Estimated completion is 2015-11.
What conditions does trial NCT01522937 study?
This clinical trial studies the following conditions: Liver Cancer, Hepatocellular Cancer.
What interventions are being tested in trial NCT01522937?
The interventions under investigation include: individualized Stereotactic Body Radiation Therapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT01522937?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01522937 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
RECRUITING · Phase 2
-
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
Y-90 Treatment Response Using Transarterial Radioembolization
RECRUITING · Phase 2
-
Domvanalimab and Zimberelimab in Advanced Liver Cancers
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.